Illumina Inc. has introduced PromoterAI, a groundbreaking AI algorithm that deciphers pathogenic regulatory genetic variants in noncoding regions of the human genome. Published in Science on May 29, 2025, a study highlights how this deep learning technology identifies promoter variants contributing to 6% of rare disease causes, accelerating diagnostic breakthroughs.
PromoterAI addresses a critical gap in rare disease diagnosis, where only 30% of patients receive accurate results from exome sequencing. Noncoding regions, comprising over 98% of the genome, often hold undiscovered insights. By interpreting promoter sequences—key noncoding elements that regulate gene transcription—PromoterAI enables precise identification of variants that disrupt gene expression, offering hope for improved diagnostic rates.
Built on advanced deep learning neural networks, PromoterAI delivers unmatched precision in analyzing promoter variants. “Illumina is breaking new ground with this AI technology,” said Kyle Farh, MD, PhD, vice president, distinguished scientist, and head of the Illumina Artificial Intelligence Lab. “Combined with whole-genome sequencing, we believe PromoterAI holds the power to improve the rate of rare disease diagnosis by identifying previously overlooked variants in the noncoding genome.” This technology empowers clinical researchers to better understand rare disease etiology and identify potential drug targets.
PromoterAI complements Illumina’s existing AI tools, SpliceAI and PrimateAI-3D, which interpret noncoding splice mutations and protein-coding variants, respectively. Together, these tools double the diagnostic yield compared to relying solely on protein-truncating variants. Integrated into Illumina Connected Software and DRAGEN secondary analysis, PromoterAI streamlines workflows for researchers, bioinformaticians, and clinical geneticists, enhancing precision medicine applications in rare diseases and oncology.
Illumina’s PromoterAI marks a significant advancement in genomic research, enabling faster and more accurate diagnoses for rare disease patients. By transforming complex genomic data into actionable insights, this technology strengthens the foundation for precision medicine and future therapeutic discoveries.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.